Physician profile
William A Todd
NPI 1558534909
$3,124.85
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $696 · 2021: $561 · 2022: $701 · 2023: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $910.83 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Gilead Sciences, INC. | $300.86 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $253.28 | 2019-2023 | |
| Abbvie INC. | $230.70 | 2019-2022 | |
| Amgen INC. | $194.67 | 2019-2022 | |
| Lilly USA, LLC | $170.46 | 2019-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $123.87 | 2020-2023 | Zerbaxa, Dificid, Recarbrio |
| Alkermes, INC. | $101.10 | 2019-2023 | Vivitrol |
| Grifols USA, LLC | $85.29 | 2019-2023 | Xembify, Prolastin-C Liquid |
| Sanofi Pasteur INC. | $72.28 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $71.38 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $71.18 | 2019 | |
| Astellas Pharma US INC | $63.19 | 2019-2023 | Cresemba |
| Sanofi-Aventis U.S. LLC | $59.23 | 2019-2020 | |
| Insmed, INC. | $55.36 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43.63 | 2019-2021 | |
| Eisai INC. | $35.86 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.56 | 2019 | |
| Amarin Pharma, INC. | $32.97 | 2021 | |
| Sunovion Pharmaceuticals INC. | $24.83 | 2019 | |
| Daiichi Sankyo INC. | $24.00 | 2021 | |
| Indivior INC. | $23.34 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.28 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.97 | 2023 | Rebyota |
| Corcept Therapeutics | $17.67 | 2023 | Korlym |
| Seqirus USA INC | $16.24 | 2020 | |
| Mylan Specialty L.P. | $15.90 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.27 | 2019 | |
| Allergan, INC. | $14.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.26 | 2023 | Farxiga |
| Romark Laboratories, Lc | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.